Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2025-03-27 Annual Report
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
Annual Report 2024
Annual Report Classification · 100% confidence The document is explicitly titled 'Infant Bacterial Therapeutics AB (publ) Annual Report 2024'. It contains comprehensive sections typical of an annual report, including a message from the CEO, a director's report, financial statements (income statement, balance sheet, cash flows), notes, and an auditor's report. It covers the fiscal year ending December 31, 2024. It is clearly the full annual report, not an announcement or a summary. FY 2024
2025-03-27 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Bokslutskommuniké 1 januari – 31 december 2024' (Year-end report) for Infant Bacterial Therapeutics AB. It contains comprehensive financial statements, including income statements, balance sheets, cash flow data, and management commentary regarding the fiscal year and the fourth quarter. It is a substantive financial report for a period shorter than a full fiscal year (in the context of the year-end release, it serves as the final quarterly/interim report before the full annual report). It meets the criteria for an Interim/Quarterly Report (IR) as it provides detailed financial data and analysis. FY 2024
2025-02-13 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Year-end report January 1 – December 31, 2024' for Infant Bacterial Therapeutics AB. It contains comprehensive financial statements, including income statements, cash flow data, balance sheet summaries, and detailed management commentary on financial performance and business operations for the full fiscal year and the fourth quarter. It is a formal financial report covering a period shorter than a full fiscal year (in the context of the quarterly breakdown) and the full year, fitting the definition of an Interim/Quarterly Report. FY 2024
2025-02-13 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive interim financial report for Infant Bacterial Therapeutics AB (publ) covering the period from January 1 to September 30, 2024. It includes detailed financial statements, management commentary (VD Kommentarer), analysis of financial development, and risk disclosures. It is clearly a substantive financial report rather than an announcement or summary, fitting the definition of an Interim/Quarterly Report. 9M 2024
2024-11-14 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January 1 – September 30, 2024' for Infant Bacterial Therapeutics AB. It contains comprehensive financial statements, including income statements, cash flow data, and balance sheet information for the third quarter and the nine-month reporting period. It also includes a 'Message from the CEO', 'Financial development' analysis, and 'Risks and uncertainties' section. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2024
2024-11-14 English
Infant Bacterial Therapeutics AB (publ) meddelar att valberedningen inför årsstämman 2025 bildats
AGM Information Classification · 95% confidence The document is a press release from Infant Bacterial Therapeutics AB announcing the formation of its nomination committee (valberedningen) for the 2025 Annual General Meeting. It details the members of the committee and provides contact information for shareholders to submit proposals. This type of announcement regarding board-related governance processes and committee formation falls under general regulatory announcements as it does not constitute a full proxy statement, a specific voting result, or a report publication announcement.
2024-10-09 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.